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Abstract                                       
The mechanisms of brain injury in sepsis are not well characterized despite the significant brain 
dysfunction that sepsis-survivors experience. CCL11 levels are dysregulated in a number of 
neurodegenerative disorders and aging1. Our research aims to better understand whether CCL11 
plays a role in regulating brain homeostasis in sepsis, given the current literature does not have 
much information on CCL11 in this context. We find that our CCL11 levels are elevated in the 
brain after sepsis in a murine model. We show that both Ki-67 and Mcm2 expression, markers of 
cell proliferation, are decreased in the neurogenic subventricular zone and dentate gyrus after 
sepsis, and rescued by neutralization of CCL11. By quantifying Iba1 expression, we find that 
CCL11 also increases microglial activation and neuroinflammation. Together this shows that 
CCL11 not only has a role in inhibiting neurogenesis but also for activating inflammatory 
immune cells in the neurogenic niche. 
 
Introduction 
Sepsis is characterized by a set of systemic inflammatory reactions in response to intensive 
infection that cannot be locally contained by the host2. Over 1.3 million patients survive sepsis 
every year in the United States alone, but survivorship comes with the burdens of long-term 
brain dysfunction, mood disorders, and chronic illness3,4. The mechanisms of brain injury in 
sepsis are not well characterized despite the significant brain dysfunction that those that have 
sepsis may experience. Given the significant disability that sepsis survivors experience, studying 
the pathologic processes that continue after illness is necessary to reduce the effects of sepsis. 
 
Patients who die of sepsis have multiple forms of brain pathology, including inflammation and 
breakdown of the blood brain barrier (BBB)5. However, it is not possible to study these 
processes in sepsis survivors because they require examining brain tissue. Animal models have 
demonstrated long-lasting inflammation in the brains of animals that survive sepsis6–8. Our 
laboratory currently uses a model of abdominal sepsis, cecal ligation and puncture (CLP) to 
study the long-term effects of sepsis in mice6. Given the public health impact of sepsis survival, 
comparatively little research has been done to understand the mechanisms that sustain brain 
dysfunction after sepsis, and there have been no trials of interventions to decrease the long-term 
effects of sepsis after it has been resolved9.  
 
Our aims strive to improve upon the current research of sepsis that exists. In our current model of 
murine sepsis, we induce sepsis in mice through CLP and study the brains of animals that 
recover from this illness6. This allows us to measure gene and protein expression throughout the 
whole brain and view the infiltration of inflammatory cells. CLP has shown to stimulate the 
innate immune response, which includes significant activation of microglia and the expression of 
cytokines10. Monocytes and astrocytes are also important sources of cytokines and may possibly 
play a role in ongoing neuroinflammation11. By studying these different cells through the 
stimulation of sepsis through a murine model, the goal is to understand the mechanisms of brain 
injury in patients who survive sepsis or critical illness.  
 
In our laboratory’s study of brain inflammation after sepsis, we have found that levels of the 
cytokine CCL11, also known as eotaxin, are elevated in the brains of sepsis survivor mice for at 
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least two weeks after sepsis. In both mice and humans, CCL11 levels also increase in plasma and 
cerebrospinal fluid with aging. Recent studies have shown that chemokines such as CCL11 may 
directly contribute to degenerative processes in the central nervous system (CNS) 1,12–16. Not 
only has it been suggested that CCL11 is dysregulated during neurodegenerative disorders, but 
also that increasing the systemic level of CCL11 causes inhibition of adult neurogenesis and 
impairment of learning and memory1,12. When compared to healthy controls, levels of CCL11 
are elevated throughout the plasma in Alzheimer’s disease, Huntington’s disease, progressive 
multiple sclerosis, and schizophrenia12,16. By identifying if CCL11 signaling is active after 
sepsis, steps can be made to identify the pathways for sepsis-induced brain dysfunction 
treatment, especially because inhibitors of CCL11 signaling have been tested in other diseases 
and are safe for use in humans17. The goal of the study was to determine if CCL11 during active 
sepsis contributes to the suppression of neurogenesis. Given CCL11’s potential role in 
suppressing neurogenesis, further research must be done to identify the mechanism in which this 
chemokine impacts sepsis survivors.  
 
Background 
Sepsis and the Innate Immune System  
Sepsis is a clinical syndrome that results from a complex interaction between the host and 
infectious agents and is characterized by the activation of multiple inflammatory pathways 
creating a systemic inflammatory response to infection18. During sepsis, the innate immune 
system is dysregulated and cellular and metabolic changes occur18. Cells and tissues such as the 
vascular endothelium, the heart, and the brain that are not routinely exposed to pathogens 
produce a significant inflammatory burst upon initial exposure and are subsequently followed by 
monocytes and macrophages infiltration into tissue19. Monocytes and macrophages produce 
cytokines and chemokines through the induction of early response genes such as TNF-α and IL-
6. These cytokines, including CCL11, amplify the early inflammatory response by recruiting 
neutrophils to the infected site, which express pathogen killing oxygen-free radicals19. It is a 
disruption in the normal immune response that causes excessive pro-inflammatory cytokine 
response and eventually sepsis. To induce sepsis in rodents, our laboratory uses a reproducible, 
titratable, naturalistic CLP model that imitates the clinically relevant human condition2,6. Our 
previous research shows that sepsis survivor mice continue to experience significant 
neuroinflammation for months after CLP and that brain dysfunction persists at 50 days post-
CLP6.  
 
Regions of Neurogenesis in Rodents 
Studies have shown that neurogenesis is primarily present in young rodents and drastically 
decreases with aging 22–24. Mammalian adult neurogenesis occurs primarily in two regions of the 
brain: the subventricular zone (SVZ) along the lateral ventricle and the subgranular zone of the 
dentate gyrus (DG) of the hippocampus20,25. The neuronal precursor cells in these areas migrate 
and differentiate into new neurons of the olfactory bulb in SVZ neurogenesis and the 
hippocampus in the DG neurogenesis25. 
 
Neuronal Cell Cycle and Biochemical Markers 
For a cell to develop into a neuron, there must be cell division and cell differentiation. Both of 
these processes are very carefully regulated and coordinated by molecules that direct the cell 
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cycle 26,27. Our research tested Ki-67, Mcm2, and 5’-bromo-2’-deoxyuridine (BrdU) as markers 
of dividing cells.  
 
Ki-67 has been used frequently as a marker of cell proliferation, as it is expressed in dividing 
cells for the majority of the mitotic process (G1, S, G2, and M phases) 28. Ki-67 is a large nuclear 
protein that undergoes phosphorylation and dephosphorylation during mitosis and shares 
structural similarities with other cell-cycle regulatory proteins29. While the function of Ki-67 is 
not known, it has been used as a reliable marker of mitosis due to its consistent expression during 
mitosis, confinement to the nucleus, and short half-life. Most importantly, studies have shown 
that Ki-67 is expressed during mitosis in all mammalian species, including rodents and humans.  
 
Mcm2 has been reported as a marker of cells actively undergoing proliferation30. Mcm2 is a 
protein that is involved in the formation of the pre-replicative complex necessary for the 
initiation of DNA synthesis. Mcm2 has been seen to be expressed during the G1 and S phase30.  
Studies have reported that there is a high correlation between Mcm2 and Ki-67 but 
immunohistochemistry for Mcm2 consistently identifies a higher proportion of dividing cells 
than Ki-67. Given the rate of neurogenesis in adult mammals is relatively low, Mcm2 might 
prove useful to identify a greater cell population. 
 
BrdU is the third marker of cell proliferation that we used. Rodents injected with BrdU have the 
thymidine analog incorporated into their DNA at the time of DNA synthesis, allowing for birth 
dating of cells. By injecting mice with BrdU the days leading up to euthanasia and then staining 
brain tissue for the marker, observation of how and when proliferating cells are being generated 
from diving their respective progenitor cells in the regions previously identified can be done29. 
One drawback of using BrdU is the stressful injection procedure and uncertain uniformity in 
BrdU expression in targeted cells.   
 
Impacts of Neuroinflammation on Neurogenesis 
When the inflammatory response occurs in the CNS, it is known as neuroinflammation20. This 
process is characterized by the activation of microglia and astrocytes, subsequent increase in 
cytokine and chemokines, and eventual disruption of the BBB that leads to the migration of 
circulating immune cells to the injury site. While neuroinflammation can be protective in the 
short-term, chronic inflammation due to lipopolysaccharide infusion can lead to neuronal 
damage and impairment of neurogenesis20. It has been shown that activated microglia, which 
secrete TNF-α, IL-6, and IL-1, lead to decreased proliferation, survival and neuronal 
differentiation.  
 
More recently CCL11, which historically has been studied in an allergic reaction framework, has 
been reported to be linked to adult neurogenesis and aging, leading to questions regarding the 
chemokine’s presentation in sepsis survivors which have decreased neurogenesis1. We 
hypothesized that CCL11 has a role in microglial activation and tested this by measuring Iba1 
immunoreactivity. 
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Emerging Literature on the Importance of CCL11 in Neurogenesis 
The potential importance of CCL11 came to our attention when Villeda’s The Ageing Systemic 
Milieu Negatively Regulates Neurogenesis and Cognitive Function was published in Nature1. By 
using heterochronic parabiosis, the study showed that blood-borne factors, including CCL11, 
present in the systemic milieu could inhibit neurogenesis in an age-dependent fashion in mice. 
The study further concluded that increasing levels of CCL11 was shown to be correlated with 
reduced neurogenesis in heterochronic parabionts and aged mice. They also showed that 
increasing peripheral CCL11 chemokine levels (in vivo) in young mice decreased adult 
neurogenesis and impaired learning and memory1.  
 
In recent years, there has been an emergence of literature related to CCL1112–16. Smith’s The 
Systemic Environment: At the Interface of Aging and Adult Neurogenesis synthesized and 
reviewed current research on how age-related changed in blood, blood-borne factors and 
peripheral immune cells contribute to the decline in adult neurogenesis and potential neurogenic 
niche-mediated mechanisms15. He refers to Villeda’s study as a forefront driver of demonstrating 
how the immune-related molecular and cellular changes in the gaining systemic environment 
negatively regulate adult neurogenesis. The review also highlights how age-related decline in 
neurogenesis can be ameliorated by exposure to the young systemic environment and may lead 
to potential treatments in the future. While the mechanisms driving the decline in neurogenesis 
with aging are not well known, Smith hypothesizes that circulating factors directly modulate 
neural stem/progenitor cell function or by indirectly altering signaling in the local neurogenic 
niche. Huber’s research supports this mechanism by concluding that since CCL11 is capable of 
crossing the blood-brain barrier of normal mice then CCL11 produced in the periphery mostly 
likely exerts physiological and pathological actions in the CNS12.  
 
Other studies that have built off of Villeda’s initial work include a group that found that young 
bone marrow transplantation preserves learning and memory in older mice14. Studies have 
reported that CCL11 levels were lower in young bone marrow recipients and led to the 
preservation of synaptic connections and reduced microglial activation in the hippocampus. On 
the other hand, when young mice were administered with CCL11, the opposite effect occurred 
and these mice had reduced synapses and increased microglial activation. Clinical studies of the 
effects of CCL11 have begun in a number of neurodegenerative disorders and psychiatric 
disorders including schizophrenia16. It was reported the CCL11 levels had a strong impact on 
memory and sustained attention including development in formal thought disorders and 
psychopathology and that further research should be conducted to see if CLL11 inhibitors could 
be a novel therapy. 
 
All of these previous studies have solidified the importance of prolonged exposure of CCL11 in 
aging. Looking at sepsis as an acute disease state, we are interested in CCL11 exposure in a 
much shorter time frame – including questions of if the amount of CCL11 that is physiologically 
produced can have a significant effect in a short period of time and is CCL11 an important driver 
of changes of neurogenesis post-sepsis compared to the myriad of cytokines that are also 
produced. Despite the large burden of long-term brain dysfunction that sepsis survivors 
experience, there is a lack of literature characterizing the role of CCL11 in inhibiting 
neurogenesis after sepsis. Through our research, we hope to fill this research gap and eventually 
propose potential therapeutic methods in combating cognitive decline after a severe illness 
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Approach 
Our aim is to determine how long after sepsis neurogenesis is suppressed and if CCL11 during 
acute sepsis contributes to suppression of neurogenesis. Trials were conducted with several 
cohorts of mice, examining markers of early neurogenesis such as Ki-67, Mcm2, and BrdU. 
Microglial activation and neuroinflammation were measured with Iba1 expression. Mice were 
also tested at both a more acute and longer time point. Naive or post-CLP mice were treated with 
isotype or anti-CCL11 antibody. Cohorts of animals were then examined at 96-hours then brains 
were stained for previously indicated markers. This may be repeated for a cohort of mice that are 
euthanized at 14 days and 6 weeks post-CLP in the future. 
 
Materials and Methods 
Mice 
Wild-type mice used in the experiment were male C57BL/6 mice from Jackson Laboratory. 
 
Cohort Set-Up and Injections 
Using a murine model with three groups of mice, we determined the effects of CCL11 inhibition. 
Our groups include: 
 
      Mouse (unoperated) + Control IgG 
      Mouse + CLP + Control IgG 
      Mouse + CLP + Neutralizing antibody against CCL11 
 
Having three different cohorts of mice allows us to account for the effect of sepsis on brain 
inflammation, the specific effect of CCL11 neutralization, and the nonspecific effects of 
injecting mice with antibodies. 
 
One of the cohorts was injected with an inhibitory antibody, specifically clone 42285, which 
targeted CCL11 and clear the cytokine from the circulation.31 As we speculate that CCL11 is 
coming from the circulation, inhibiting CCL11 itself rather than its receptor is likely to be 
effective even if the antibody does not pass the blood brain barrier. One of the other cohorts was 
injected with negative control mouse IgG which is used as a negative control for our inhibitory 
antibody. Negative control mouse IgG being used in place of the antibody allowed us to evaluate 
the nonspecific effects of injecting antibody on the immune system.32All mice were injected with 
BrdU (100mg/kg) daily after CLP and before euthanization so that proliferating cells could later 
be stained. BrdU was given at this time point so that we could identify proliferating cells after 
inflammation was established but still early after sepsis, all in conjunction with the CCL11-
antibody.  
 
By modifying CCL11 levels by intraperitoneal injection of an anti-CCL11 antibody, which has 
previously been shown to decrease CCL11 levels and increase neurogenesis in aged animals in 
the setting of exogenous CCL11 administration, we were able to identify the continuous effect of 
the antibody during the early stages of sepsis.1 We injected 50 mcg/kg of the antibody on the day 
of CLP and 48 hours after CLP (Figure 1).  
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Cecal Ligation and Puncture (CLP)  
Cecal ligation puncture procedure (CLP) consists of the perforation of the cecum which allows 
the release of fecal material into the peritoneal cavity2. This induces an immune response to a 
polymicrobial infection which simulates the multiple and overlapping mechanisms involved in 
sepsis. Most importantly, it is shown the mice share a similar cytokine profile seen in human 
sepsis when CLP is performed.2 We used a 19 gauge needle in which we would then expect a 
60% survival rate for the mice; this ensures that the survivor mice did indeed experience sepsis 
and minimizes survivor bias.  
 
ELISA for CCL11 
Mice were euthanized and transcardially perfused with PBS. Brain hemispheres were then frozen 
in liquid nitrogen.  Protein containing homogenates were prepared by homogenizing frozen brain 
hemispheres with a rotor/status (Tissue Tearor) in RPMI medium. The raw homogenates were 
then cleared of particles by centrifugation at 20,000 x g for 30 minutes. CCL11 was quantified 
using anti-mouse CCL11 ELISA (R&D Systems).    
 
Histology  
Mice were euthanized and transcardially perfused with PBS and 4% paraformaldehyde at 96 
hours post CLP. The brains were then removed, rinsed, and immersed in a buffered 30% sucrose 
solution until no longer buoyant. Cryoprotected tissues were then frozen on dry ice and stored at 
-80°C. Once the brains were needed for immunohistochemistry, we sectioned the brains into 40-
micron sections using a cryostat. Tissue was stored at -20oC in cryoprotectant solution.  
 
Immunofluorescence for CCL11 
Sections were rinsed of cryoprotectant and then mounted on Superfrost Plus slides.  Sections 
were then blocked and permeabilized (Tris-buffered saline with 10% serum and 0.4% Triton-X) 
and then incubated with anti-CCL11 antibody (capture antibody from R&D systems ELISA) 
overnight at 4C.  Sections were then washed and incubated with Alexa 488 conjugated secondary 
antibody for 2 hours, washed, and coverslipped in antifade medium.   
 
Immunohistochemistry with DAB Peroxidase for Ki-67 and MCM2 
Sections were first processed using a free-floating technique. Endogenous peroxidases were 
deactivated by treatment with 1% H2O2 and then washed with Tris buffer and TBS. Sections 
were then mounted to Superfrost Plus slides. The slides were then blocked and permeabilized by 
incubation with blocking buffer (Tris + 10% NGS/NHS + 0.4% Triton-X). Sections were 
incubated with anti-Ki-67 antibody (Cell Signaling D3b5, 1:400) or anti-MCM2 (Abcam, 1:200) 
overnight at room temperature. Sections were then washed and incubated with biotinylated horse 
anti-rabbit IgG secondary antibody (Vector, 1:200) for 90 minutes at room temperature. Sections 
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were washed again and then incubated with Vector Elite ABC solution for 1 hour. The tissue was 
reacted with DAB Peroxidase until fully developed. The sections were dried, dehydrated and 
cleared with washes in progressive (70%, 95%, 100%) ethanol solution and finally xylene. The 
tissue was coverslipped with Permount.  
 
Immunohistochemistry with Tyramide Signal Application (TSA) for BrdU  
Sections were processed using a free-floating technique. DNA was denatured with 2 
hydrochloric acid for 30 min at 37o C and then neutralized with 0.1 M sodium borate for 10 min. 
Endogenous peroxidases were deactivated by treatment with 1% H2O2, followed by incubation 
with blocking buffer (10% NGS + 3% BSA + 1% glycine + 0.4% Triton-X in Tris-buffered 
saline). Sections were washed and mounted to Superfrost Plus slides. Sections were incubated 
with rat anti-BrdU antibody (AbD Serotec Clone: BU 1/75, 1:200) overnight at room 
temperature. Sections were then washed and incubated with biotinylated horse anti-rat and anti-
rabbit IgG secondary antibody (Vector, 1:200) for 30 minutes at room temperature. To amplify 
the secondary antibody signal, we incubated each tissue section with 10 l tyramide for 3 
minutes. The sections were then washed and coverslipped in Antifade. 
 
Immunofluorescence for Iba1 
Sections were processed using a free-floating technique. Sections were washed with TBS to 
remove cryoprotectant and then mounted to Superfrost Plus slides. The slides were then blocked 
and permeabilized by incubation with blocking buffer (10% NHS + 3% BSA + 1% glycine + 
0.4% Triton-X in Tris-buffered saline). Sections were incubated with anti-goat Iba1 antibody 
(Wako, 1:500) overnight at -4oC. Sections were then washed, blocked, and incubated with anti-
goat Alexa 488 secondary antibody for 120 minutes at room temperature. The sections were then 
washed and coverslipped with Prolong Gold.  
 
Counting of Ki67 and Mcm2 positive nuclei 
The number of Ki67 or Mcm2 positive nuclei was counted in the SVZ and SGZ. Every 12th 
serial section was examined. For the SVZ, cells in sections from the anterior extent of the SVZ 
posteriorly to the fornix were counted. Cells were counted in the wall of the lateral ventricle and 
the rostral migratory stream. For the SGZ, cells were counted in all sections which demonstrated 
a distinct dentate hilus and granular cell layer. Cells were counted within a two-nucleus span 
from the border between the hilus and granular cell later. Cells were exhaustively counted 
through the entire thickness of each section, given the wide spacing of sections. Total counts per 
SVZ or SGZ were calculated by averaging counts from the left and right side of each section and 
then multiplying by 12.   
 
Quantification of Iba1 staining 
Iba1 stained sections at the level of the mid hippocampus were imaged using a Leica SP8 
confocal microscope. 1-micron optical sections were taken through a 20-micron volume of each 
section and transformed into a maximum intensity projection. To determine the Iba1+ area of 
each section, images were thresholded at the level that identified the cell body of microglial 
cells. Single-pixel noise was eliminated by using the “erode” option in ImageJ, eliminating any 
pixel that is not adjacent to at least two other positive pixels.   
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Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCL11 levels in the brain are elevated due to migration from the periphery rather than 
local production post-CLP.  
We first sought to confirm that CCL11 levels are elevated in the brain post-CLP. After 
conducting CLP and injections, our data showed a 100% survival rate for anti-CCL11 injected 
mice and around a 60% survival rate for isotype injected mice (Figure 2A). Next by performing 
ELISAs, we found that CCL11 levels are elevated in mice that survive sepsis in comparison to 
unoperated healthy mice two weeks after sepsis (Figure 2B). In this same model, sepsis results in 
the infiltration of inflammatory cells such as neutrophils and monocytes that lasts for at least two 
weeks after sepsis. As CCL11 is capable of crossing the BBB in healthy mice, it is possible that 
CCL11 is produced in the periphery and has the ability to infiltrate and harm the CNS12. Using 
immunohistochemistry, we wanted to determine if the CCL11 was being produced locally in the 
brain or was being recruited from the periphery. Current images show an increase of CCL11 
found near blood vessels (Figure 2C). Increased diffuse perivascular staining, which is shown 
with the arrowheads, is prevalent in sepsis survivor mice compared to unoperated control mice. 
This data leads us to hypothesize that elevated levels of CCL11 is due to synthesis by vascular or 
perivascular cells and then migration across the BBB, rather than being produced by localized 
brain cells such as microglia. 
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Figure 2. Sepsis survivor mice show an elevated expression of CCL11 due to recruitment and 
migration across the BBB.  
A: Survival data for post-CLP anti-CCL11 and isotype injected mice.  
B: CCL11 expression levels in unoperated and CLP mice.  
C: Immunofluorescent imaging shows that in post-CLP mice, there is greater diffuse perivascular CCL11 
staining in the lateral ventricle. 
LV 
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Ki-67 expression is elevated in neurogenic SVZ in mice that were treated with anti-CCL11. 
To analyze the impacts of CCL11 on neurogenesis, we conducted DAB/Ki-67 staining. Initially, 
we stained for BrdU with Tyramide but the samples showed too few cells to make a reliable 
statistical differentiation between conditions so we continued with other cell proliferation 
markers (Figure 3A-B). We counted serial sections in a blinded fashion that contained Ki-67 
positive cells located in the SVZ (Figure 3C). We compared the cell counts by ANOVA. We 
found that there were statistically significant increases in Ki-67 expression in the neurogenic 
sub-ventricular zone in anti-CCL11 injected mice compared to isotype treated sepsis survivor 
mice (96 hours post-CLP), leading us to believe that the lack of neurogenesis in sepsis may be 
mediated by CCL11 (Figure 3D). However, while the cells in the SVZ demonstrated robust 
immunoreactivity for Ki67, only a few cells were seen in the SGZ, making this marker 
unsuitable for that region. We thus explored the utility of Mcm2 as a better marker of cell 
division in both neurogenic regions.    
 
 
 
LV
Ki67
Naive CLP, isotype treatment CLP, anti-CCL11 treatment
Figure 3. Anti-CCL11 mice have greater expression 
levels of Ki-67 compared to isotype treated mice. 
A-B: Staining for BrdU showed too few cells to 
differentiate between conditions (only unoperated is 
shown) 
C: Imaging of Ki-67 positive cells in SVZ for naïve, 
CLP + isotype, CLP + anti-CCL11. 
D: Estimated Ki-67 positive cells in the SVZ of isotype 
and anti-CCL11 mice.  
C 
A B 
D 
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Mcm2 expression is rescued in both neurogenic regions (SVZ, DG) for mice that are 
treated with anti-CCL11 antibody. 
With our Tyramide and DAB immunohistochemistry protocol, we conducted Mcm2 staining and 
found that it showed the best staining results for both neurogenic regions out of all three of our 
potential cell proliferation markers (Figure A-I). We counted serial sections in a blinded fashion 
that contained Mcm2 positive cells located in the SVZ and DG using brightfield microscopy 
(Figure 4D-I). We then compared the cell counts by ANOVA. Imaging and cell counts show 
distinct differences between CLP + anti-CCL11 and CLP + isotype cohorts with Mcm2 positive 
cell expression being statistically higher and lower respectively. This leads us to conclude that 
blocking CCL11 in the brain leads to a rescuing effect for neurogenesis, as shown with elevated 
Ki-67 and Mcm2 expression levels in our anti-CCL11 treated mice.  
Figure 4. Anti-CCL11 treatment rescues neurogenesis in both the SVZ and DG.  
A-C: Initial test of tyramide staining of Mcm2 positive cells in the SVZ in the three murine cohorts.  
D-I: Imaging of Mcm2 positive cells in the SVZ and DG for all three murine cohorts. There is distinct rescue 
effect of Mcm2 positive cells in anti-CCL11 treated mice.  
J-K: Mcm2 positive cell counts in the SVZ and DG for all three murine cohorts. There is statistically significant 
difference in cell counts between CLP + isotype and CLP + anti-CCL11 treatment, but not between naïve + 
isotype and CLP + anti-CCL11 treatment  
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CCL11 increases microglial activation  
As stated earlier, neuroinflammation can be protective in 
an acute timeframe, but chronic inflammation can lead to 
impairment of neurogenesis. To complement the previous findings in CCL11’s role in inhibiting 
neurogenesis, we wanted to see if CCL11 played a role in the regulation of microglial activation. 
We stained tissue from our three murine cohorts with Iba1, a known marker of microglia. 
Neutralizing CCL11 decreases microglial activation and neuroinflammation to a similar 
phenotype to unoperated mice. This confirms our hypothesis that CCL11 has a role in microglial 
activation and neuroinflammation post-sepsis.  
 
Discussion 
Long-term brain dysfunction, cognitive decline, and chronic disability are a few of the 
significant clinical problems that sepsis survivors experience. Despite the burden that sepsis 
survivors experience, the mechanisms of brain injury in sepsis are not well characterized. Our 
goal is to improve upon the current research of sepsis that exists, using a CLP model to study the 
acute inflammatory response in brains of mice that recover from this illness.  
 
During our study of brain inflammation after sepsis, we found that levels of CCL11 were 
elevated in the brains of sepsis survivor mice. This intrigued us to see what literature exists 
regarding the potential importance of CCL11. As previously described, it has been suggested that 
increasing the levels of CCL11 leads to inhibition of adult neurogenesis1-12. Villeda’s The Ageing 
Systemic Milieu Negatively Regulates Neurogenesis and Cognitive Function was a seminal work 
in showing that increasing peripheral CCL11 levels in vivo lead to decreased adult neurogenesis 
and impaired learning and memory11. Building off of Villeda’s work it has been hypothesized 
that circulating factors, such as cytokines, that are able to pass the BBB and directly regulate 
neurogenesis and stem cell function by altering the signaling that occurs within neurogenic 
regions. Further studies have focused on the administration of CCL11 in younger mice and saw 
increased neuroinflammation and decreased number of synapses14. Other clinical studies have 
begun to study the effects of CCL11 in schizophrenia and could be replicated in Alzheimer’s, 
D 
Figure 5. CCL11 plays a role in microglia activation, 
neuroinflammation and impairment of neurogenesis.   
A-C: Imaging of Iba1 positive pixels in the DG for all 
three murine cohorts.  
D: Percent Iba1 positive pixels in the area for all three 
murine cohorts 
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Huntington’s disease and progressive multiple scelerosis12,16. Despite the newly emerging 
literature on CCL11, there is still a lack of literature characterizing the role of CCL11 in 
inhibiting neurogenesis after sepsis. Our goal was to fill this research gap and propose future 
directions which would eventually lead to potential therapeutic methods in combating cognitive 
decline after a severe illness. 
 
Here, we showed that our CCL11 levels are elevated in the brain post-CLP due to migration 
from the periphery rather than local production. We also showed that both Ki-67 and Mcm2 
expression is rescued in neurogenic SVZ and also for Mcm2 in neurogenic DG for mice that are 
treated with anti-CCL11. By quantifying Iba1 expression, we found that CCL11 also increases 
microglial activation. This shows that CCL11 not only has a role in inhibiting neurogenesis but 
also for activating inflammatory immune cells in the neurogenic niche. 
 
There are a few limitations in our studies. While MCM2 and Ki67 are markers of the cell cycle, 
their expression is detectable for days and thus may not truly represent events that occur exactly 
at the time of induction of sepsis. Using BrdU to definitively labels cells that divide at a specific 
time point after sepsis would be more precise. Although we administered BrdU to the mice 
examined in this study, we had difficulty visualizing sufficient cells to quantitatively compare 
the different treatment conditions. We are continuing to work on increasing the sensitivity of this 
staining protocol. A second limitation is that we have not determined whether the changes in 
rates of cell proliferation that we observed here will lead to changes in the number of newborn 
neurons several weeks after cell division. In order to do this, we would need to count the number 
of BrdU+ cells labeled during the period after sepsis that ultimately begin to express a neuron-
specific marker, such as doublecortin, several weeks later. Finally, we have not determined how 
long suppression of neurogenesis persists after sepsis since we have only examined one early 
timepoint following CLP 28–30,33,34. We are currently continuing to conduct TSA staining for 
BrdU with a larger murine cohort euthanized at 14 days following CLP so that we can more 
accurately assay how long after sepsis neurogenesis is suppressed and if CCL11 during acute 
sepsis contributes to suppression of neurogenesis.  
 
Someone researchers may question the magnitude and impact of neurogenesis in humans, given 
the role of new neurons in adult humans is yet to be determined 25,35. We propose that research 
regarding neurogenesis post-sepsis in rodent models of sepsis is important as neurogenesis may 
serve as a surrogate indicator of brain injury and homeostasis. Neurogenesis is an extremely 
sensitive process and is impacted before other downstream immune processes may occur. 
Furthermore, CCL11 signaling may directly or indirectly affect a broad variety of brain 
processes in addition to neurogenesis, as suggested by our finding that CCL11 neutralization 
modifies microglial reactivity.  
 
While our research has shown that CCL11 inhibits neurogenesis after sepsis, there is still much 
to uncover, including (1) how long neurogenesis is suppressed after sepsis; (2) can the blockade 
of CCR3, the canonical receptor of CCL11, also rescue neurogenesis after sepsis; (3) are 
neurogenesis dependent behaviors altered due to sepsis? Once the mechanisms of CCL11 are 
better understood, therapeutic interventions such as a CCL11 or CCR3 inhibitor can be 
developed to treat the reversible components of long-term cognitive decline after sepsis.  
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Conclusion  
We have found that CCL11 signaling in sepsis survivor mice contributes to decreased cell 
proliferation and neurogenic zones of the mouse brain and increases microglial reactivity.  
Further studies will determine how long this effect persists and whether acute decreases in cell 
proliferation after sepsis ultimately change the number of newborn neurons in the hippocampus.   
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